Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study

W M van der Flier, E C W van Straaten, F Barkhof, J M Ferro, L P Pantoni, A M Basile, D Inzitari, T Erkinjuntti, L O Wahlund, E Rostrup, R Schmidt, F Fazekas, P Scheltens, on behalf of the LADIS study group

Objective: To assess the associations of medial temporal lobe atrophy (MTA) and white matter hyperintensities (WMH) with cognitive function in a large group of independently functioning elderly people.

Methods: Data were drawn from the multicentre, multinational leukoaraiosis and disability (LADIS) project which is studying prospectively the role of WMH as an independent predictor of the transition to disability in non-disabled elderly people. In all, 639 participants were enrolled in the LADIS study. For the present analysis, data on 581 subjects were available. Cognitive function was assessed by the mini-mental state examination (MMSE). Visual ratings of WMH and MTA were undertaken on magnetic resonance images (MRI).

Results: The presence of either severe WMH or MTA was associated with a modest but non-significant increase in frequency of mild cognitive deficits (severe WMH: odds ratio (OR) = 1.9 (95% confidence interval (CI), 1.0 to 3.7); MTA present: OR = 1.5 (95% CI, 0.8 to 2.8)). However, subjects with the combination of MTA and severe WMH had a more than fourfold increase in frequency of mild cognitive deficits (OR = 4.1 (95% CI, 2.3 to 7.4)). Analysis of variance with post hoc Bonferroni t tests showed that subjects with both MTA and severe WMH performed worse on MMSE than those with either no MRI abnormality or a single MRI abnormality (p < 0.05).

Conclusions: These results provide further evidence for the combined involvement of both Alzheimer type pathology and vascular pathology in the earliest stages of cognitive decline and suggest an additive effect of WMH and MTA.

Methods

Data were drawn from the multicentre and multinational leukoaraiosis and disability (LADIS) project which is studying prospectively the role of WMH as an independent predictor of the transition to disability in non-disabled elderly people. The design of the LADIS project has been fully described elsewhere. In short, 639 elderly subjects who had no or only mild disability in their instrumental activities of daily living (IADL) and who were stratified for WMH severity were enrolled between 18 July 2001 and 31 January 2003. Subjects presented with complaints including mild cognitive or motor disturbances, minor cerebral events, mood alterations, other neurological problems, or in whom WMH were incidentally identified on brain imaging. Subjects participating as controls in other studies and volunteers were also included. To be included, subjects had to meet the following criteria:

- age between 65 and 84 years;
- WMH on MRI of any degree, according to the categorisation into the three severity classes of a revised version of the Fazekas scale;
- no or only mild disability as determined by the IADL scale;
- presence of a regularly contactable informant;
- agreement to sign informed consent.

Exclusion criteria were: the likelihood of dropping out because of the presence of severe illnesses (cardiac, hepatic, or renal failure, cancer, or other relevant systemic diseases); severe unrelated neurological diseases; leucoencephalopathy of non-vascular origin (immunological-demyelinating, metabolic, toxic, infectious, other); severe psychiatric disorders; severe unrelated neurological diseases; severe psychiatric disorders; severe unrelated neurological diseases; severe psychiatric disorders.

Abbreviations: IADL, instrumental activities of daily living; LADIS, leukoaraiosis and disability project; MMSE, mini-mental state examination; MTA, medial temporal lobe atrophy; WMH, white matter hyperintensities.
RESULTS

There were 581 subjects (54% female). Their mean (SD) age was 74 (5) years; their years of education, 10 (4); and their MMSE score, 27 (2). The majority of subjects had good cognitive function (n = 486, defined as MMSE score, 27 (2)). The majority of subjects had good cognitive function, whereas those with an MMSE score below 26 were considered to have “mild cognitive deficit.” Subjects with an MMSE score of 26 or more were considered to have “good cognitive function.”

All subjects were assessed using an extensive set of clinical and functional tests including global functioning, and cognitive, motor, psychiatric, and quality of life measures. For the present study, general cognitive function was assessed by the mini-mental state examination (MMSE). Subjects with an MMSE score of 26 or more were considered to have “good cognitive function,” whereas those with an MMSE score below 26 were considered to have “mild cognitive deficit.”

All subjects were assessed using an extensive set of clinical and functional tests including global functioning, and cognitive, motor, psychiatric, and quality of life measures. For the present study, general cognitive function was assessed by the mini-mental state examination (MMSE).

DISCUSSION

We showed that a combination of MTA and severe WMH was associated with a modest but non-significant increase in frequency of mild cognitive deficits (severe WMH, p = 0.06; MTA present, p = 0.23, see table 1). However, subjects with the combination of MTA and severe WMH had a more than fourfold increase in the frequency of mild cognitive deficits (p < 0.001). These risk estimates did not change essentially when age, sex, education, and the presence of stroke or lacunes were entered as covariates. Formal testing in a logistic regression model incorporating the interaction term between MTA and WMH showed that there was no statistical interaction between MTA and WMH.

In an additional analysis, we compared the MMSE score of the four “MTA x WMH” groups using ANOVA. There was a difference in MMSE score between groups (p < 0.001, fig 1). Post hoc analyses using Bonferroni tests showed that the group with both MTA and severe WMH performed significantly worse than the other three groups of subjects with either no MRI abnormality or a single abnormality (p < 0.05). The presence of either MTA but no severe WMH, or severe WMH but no MTA was not associated with a significantly lower MMSE score.

There was a significant correlation between the presence of severe WMH and MTA (Spearman’s r = 0.27, p < 0.001). The presence of either severe WMH or MTA was associated with a modest but non-significant increase in frequency of mild cognitive deficits (severe WMH, p = 0.06; MTA present, p = 0.23, see table 1). However, subjects with the combination of MTA and severe WMH had a more than fourfold increase in the frequency of mild cognitive deficits (p < 0.001). These risk estimates did not change essentially when age, sex, education, and the presence of stroke or lacunes were entered as covariates. Formal testing in a logistic regression model incorporating the interaction term between MTA and WMH showed that there was no statistical interaction between MTA and WMH.

We showed that a combination of MTA and severe WMH was associated with a more than fourfold increase in the frequency of mild cognitive deficits in a large group of non-disabled elderly people. By contrast, mild cognitive deficits were not more frequent in the groups of patients with a single MRI abnormality (either MTA or severe WMH). These results suggest the combined involvement of both Alzheimer type pathology and vascular pathology in the earliest stages of cognitive decline.

---

Table 1 Odds ratios for mild cognitive deficits dependent on medial temporal lobe atrophy and white matter hyperintensities

<table>
<thead>
<tr>
<th>Medial temporal lobe atrophy</th>
<th>White matter hyperintensities</th>
<th>Good cognitive function (n)</th>
<th>Mild cognitive deficits (n)</th>
<th>Crude odds ratio (95% CI)</th>
<th>Adjusted odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>Absent</td>
<td>302</td>
<td>40</td>
<td>1.0 (reference)</td>
<td>1.0 (reference)</td>
</tr>
<tr>
<td>Mild</td>
<td>Severe</td>
<td>56</td>
<td>1</td>
<td>1.9 (1.0 to 3.7)</td>
<td>1.9 (1.0 to 3.7)</td>
</tr>
<tr>
<td>Present</td>
<td>Mild</td>
<td>82</td>
<td>14</td>
<td>1.5 (0.8 to 2.8)</td>
<td>1.5 (0.8 to 2.8)</td>
</tr>
<tr>
<td>Present</td>
<td>Severe</td>
<td>46</td>
<td>16</td>
<td>4.1 (2.3 to 7.4)</td>
<td>4.1 (2.3 to 7.4)</td>
</tr>
</tbody>
</table>

Data are presented as odds ratios and their 95% confidence intervals (CI). Adjusted odds ratios are corrected for age, sex, education, and presence of stroke and/or lacunes.

MMSE, mini-mental state examination; MTA, medial temporal lobe atrophy; WMH, white matter hyperintensities.

---

Figure 1 Mean mini-mental state examination (MMSE) score according to the presence of medial temporal lobe atrophy (MTA) and age related white matter hyperintensities (WMH). The group with both MTA and severe WMH had a lower MMSE score than the groups with a single MRI abnormality or no abnormality (p < 0.05).
Former studies (both necropsy and MRI) reported that Alzheimer type pathology and vascular pathology often coexist in patients with dementia.\textsuperscript{1–5} The present study extends these findings, as we observed in vivo using MRI that even in non-disabled elderly people the combination of MTA and WMH was already associated with decreased cognitive performance. These findings provide further evidence for the threshold theory, which stipulates that Alzheimer type pathology and cerebrovascular pathology summate until a threshold is reached and clinical dementia ensues.\textsuperscript{10}

In seeming contrast to earlier studies,\textsuperscript{1–10,11} the presence of MTA alone was not significantly associated with cognitive impairment. The specific characteristics of the LADIS study sample probably account for this finding. Subjects were included on the basis that they had WMH on MRI in combination with absence of disability, resulting in a study population that is biased towards excessive vascular pathology and relatively little Alzheimer type pathology. However, even in this population, where cognitive impairment would be expected to be of vascular origin, the association between WMH and cognitive impairment could only be fully appreciated if MTA was also taken into account.

A possible limitation of this study includes the use of dichotomised rather than continuous measures of MTA and WMH. In addition, we used the MMSE, which is a rather crude measure of cognitive function. It is conceivable that the use of continuous MRI variables and a more sensitive cognitive test would have yielded more striking results. However, we feel that our simple approach enhances the clinical value of our results, as the MMSE is one of the most widely used cognitive tests. In addition, contrasting with sophisticated, but time intensive neuroimaging measures, simple ratings of MTA and WMH can be used in clinical practice.

These results may have important clinical implications. Memory clinics often evaluate patients who present with subjective memory complaints and severe WMH on MRI, but who have no detectable cognitive deficits. The present study suggests that if such patients have additional MTA they may be at increased risk of subtle cognitive impairment. Should further studies using a longitudinal design corroborate our finding that the combination of WMH and MTA is indeed predictive of subsequent cognitive decline, the combination of these simple MRI markers may be a useful tool in identifying subjects at risk of dementia. Whether this combination of markers predicts dementia at follow up in the present sample will be the subject of further study.

ACKNOWLEDGEMENTS

The LADIS study is supported by the European Union within the V European Framework Programme “Quality of life and management of living resources” (1998–2002), contract No QLRT–2000-00446 as a European Framework Programme “Quality of Life and Management of Living Resources.” The LADIS study is supported by the European Union within the V European Framework Programme “Quality of Life and Management of Living Resources.”

APPENDIX

LIST OF PARTICIPATING CENTRES AND PERSONNEL

Helsinki, Finland (Memory Research Unit, Department of Clinical Neurosciences, Helsinki University): Timo Erkinjuntti MD, PhD, Tarja Pohjasvaara MD, PhD, Pia Piihan MD, Raija Yliskoski PhD, Hanna Jokinen LPsych, Mejia-Marjut Somerkoski MPsy, Riitta Mäntylä MD, PhD, Olli Salonen MD, PhD; Graz, Austria (Department of Neurology and MRI Institute, Medical University): Franz Fazekas MD, Reinhold Schmidt MD, Stefan Ropele PhD, Alexandra Seewann MD, Katja Petrovic MagPsychol, Ulrike Garmehi; Lisbon, Portugal (Serviço de Neurologia, Centro de Estudos Egas Moniz, Hospital de Santa Maria): José M Ferro MD, PhD, Ana Verdelho MD, Sofia Madureira PsyD; Amsterdam, Netherlands (Department of Neurology, VU Medical Centre): Philip Scheltens MD, PhD, Ilse van Staarten MD, Alda Gouw MD, Wiesje van der Flier PhD, Frederik Barkhof MD, PhD; Göteborg, Sweden (Institute of Clinical Neuroscience, Göteborg University): Anders Wallin MD, PhD, Michael Jonsson MD, Karin Lind MD, Arto Nordlund PsyD, Sindre Rolstad PsyD, Kerstin Gustavsson RN; Huddinge, Sweden (Neurotec department, Section of Clinical Geriatrics, Karolinska Universitetssjukhuset): Lars-Olof Wahlund MD, PhD, Milita Crisby MD, PhD, Anna Pettersson, physiatrist; Kaatina Amberla PsyD; Paris, France (Department of Neurology, Hopital Lariboisiere): Hugues Chabriat MD, PhD, Ludovic Benoit MD, Karen Hernandez, Solene Pointeau, Annie Kurtz, Daniel Reizine MD; Mannheim, Germany (Department of Neurology, University of Heidelberg, Klinikum Mannheim): Michael Hennerici MD, Christian Blahak MD, Hansjorg Baenzner MD, Martin Wiarda PsyD, Susanne Seip RN; Copenhagen, Denmark (Copenhagen University Hospital: Memory Disorders Research Unit, Department of Neurology, Rigshospitaliet, and the Danish Magnetic Resonance Research Centre, Hvidovre Hospital): Gunhild Waldemar MD, DMSc, Egill Rostrup MD, MSc, Charlotte Ryberg, Tim Dyrbø; Newcastle-upon-Tyne, UK (Institute for Ageing and Health, University of Newcastle): John O’Brien DM, Sanjeet Pakrasi MRCPsych, Thais Minnet PhD, Michael Firbank PhD, Jenny Dean PhD, Pascale Harrison BSc, Phillip English DCR.

The Coordinating centre is in Florence, Italy (Department of Neurological and Psychiatric Sciences, University of Florence): Domenico Inzitari MD (Study Coordinator); Leonardo Pantoni MD, PhD, Anna Maria Basile MD, Michela Simoni MD, Giovanni Pracucci MD, Monica Martin MD, Luciano Bartolini PhD, Emilia Salvador PhD, Marco Moretti MD, Mario Macalchi MD, PhD.

The LADIS Steering Committee is formed by Domenico Inzitari MD (study coordinator), Timo Erkinjuntti MD, PhD, Philip Scheltens MD, PhD, Marieke Visser MD, PhD, and Kjell Asplund MD, PhD.

REFERENCES

Hemifacial spasm, neuralgia, and syncope due to cranial nerve compression in a patient with vertebral artery ectasia

A 42 year old woman with a history of an incompletely remitted peripheral left facial nerve palsy that was followed by clusters of hemifacial spasm and paroxysms of lancinating pain located behind the left ear and radiating to the ipsilateral eye, the neck, or shoulder, was admitted for re-evaluation due to additionally manifested short lasting syncope-like episodes of increasing frequency. Beneath a mild residual facial nerve palsy no further focal findings were documented. Extensive cardiologic workup revealed only a positive tilt table test, indicating an intense vagovascular reaction.

Re-evaluation of previously performed imaging examinations focussed on an already angiographically described tortuous course of the vertebobasilar arteries (panel A), which compressed the left lateral surface of the medulla, pons, and pontomedullary junction, as also demonstrated on MRI (panel B). Based on the documented vagovascular reaction we assumed an affection of the lower cranial nerves and additionally performed ultra thin MRI. In this way we could impressively demonstrate a severe compression of the proximal stem of the cranial nerves IX and X (panel D), and the root entry zone of the facial nerve on the left (panel C). Owing to the escalation of symptoms the patient underwent microvascular decompressive surgery with interposition of a muscle graft. Two years later she remains asymptomatic. A repeated tilt table test was this time negative.

This is an uncommon case of neurovascular compression, characterised by known, however previously not in this combination, described features such as hemifacial spasm, variant glossopharyngeal neuralgia, and syncope, which all ceased after surgery.

K Spengos, G Tsivgoulis, G Stouraitis, D Vassilopoulos
Department of Neurology, University of Athens, Athens, Greece

P Toulas
Encephailos Diagnostic Institute, Athens, Greece

E Gialafos
Department of Cardiology, Laikos Hospital, Athens, Greece

Correspondence to: Dr Konstantinos Spengos, Department of Neurology, University of Athens, Vass. Sofias 82, 11528 Athens, Greece; spengos@hol.gr

Competing interests: none declared

References

doi: 10.1136/jnnp.2005.064147
Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study

W M van der Flier, E C W van Straaten, F Barkhof, J M Ferro, L Pantoni, A M Basile, D Inzitari, T Erkinjuntti, L O Wahlund, E Rostrup, R Schmidt, F Fazekas and P Scheltens

*J Neurol Neurosurg Psychiatry* 2005 76: 1497-1500
doi: 10.1136/jnnp.2005.064998

Updated information and services can be found at:
http://jnnp.bmj.com/content/76/11/1497

These include:

**References**

This article cites 15 articles, 6 of which you can access for free at:
http://jnnp.bmj.com/content/76/11/1497#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Memory disorders (psychiatry) (1390)
- Radiology (1747)
- Radiology (diagnostics) (1309)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/